利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

87 条记录 (耗时 0.04 秒)

    Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodies
    2.
    发明授权
    Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodies 失效
    通过施用7C10和16C10 CD80特异性抗体来抑制T细胞的IL-2产生的方法

    公开(公告)号：US07491393B2

    公开(公告)日：2009-02-17

    申请号：US11840594

    申请日：2007-08-17

    申请人： Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    发明人： Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    IPC分类号： A61K39/395 ,  C07K16/28

    CPC分类号： C07K16/2827 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

    摘要： The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

    摘要翻译： 本发明涉及对人B7.1抗原（CD80）特异性并且能够抑制B7.1与CD28受体的结合并且不能抑制B7.1结合的抗体的鉴定 到CTLA-4受体。 尽管存在第二活化配体B7.2（CD86），但是这些抗体16C10和7C10中的两个显着抑制了IL-2的产生。 阻断CD28和B7.1（CD80）之间的主要激活信号与这些抗体同时允许CTLA-4和B7.1和/或B7.2的未受损或一致的相互作用代表对阳性共刺激的组合拮抗作用， 对负信号的激动作用。 这些抗体可以用作特异性免疫抑制剂，例如用于治疗自身免疫性疾病和预防器官移植排斥。

    7C10 and 16C10 CD80-specific antibodies
    4.
    发明授权
    7C10 and 16C10 CD80-specific antibodies 失效
    7C10和16C10 CD80特异性抗体

    公开(公告)号：US07417128B2

    公开(公告)日：2008-08-26

    申请号：US11553302

    申请日：2006-10-26

    申请人： Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    发明人： Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    IPC分类号： C07K16/28 ,  C12N15/13

    CPC分类号： C07K16/00 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/70532 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92

    摘要： The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-I and b7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

    摘要翻译： 本发明涉及对人B7.1抗原（CD80）特异性并且能够抑制B7.1与CD28受体的结合并且不能抑制B7.1结合的抗体的鉴定 到CTLA-4受体。 尽管存在第二活化配体B7.2（CD86），但是这些抗体16C10和7C10中的两个显着抑制了IL-2的产生。 使用这些抗体阻断CD28和B7.1（CD80）之间的主要激活信号，同时允许CTLA-1和b7.1和/或B7.2的未受损或一致的相互作用代表对阳性共刺激的组合拮抗作用， 对负信号的激动作用。 这些抗体可以用作特异性免疫抑制剂，例如用于治疗自身免疫性疾病和预防器官移植排斥。

    Nucleic acids encoding 7C10 and 16C10 CD80-specific antibodies
    5.
    发明授权
    Nucleic acids encoding 7C10 and 16C10 CD80-specific antibodies 有权
    编码7C10和16C10 CD80特异性抗体的核酸

    公开(公告)号：US07414123B2

    公开(公告)日：2008-08-19

    申请号：US11464123

    申请日：2006-08-11

    申请人： Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    发明人： Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    IPC分类号： C12N15/13 ,  C07K16/28

    CPC分类号： C07K16/2827 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

    摘要： The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signaling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

    摘要翻译： 本发明涉及对人B7.1抗原（CD80）特异性并且能够抑制B7.1与CD28受体的结合并且不能抑制B7.1结合的抗体的鉴定 到CTLA-4受体。 尽管存在第二活化配体B7.2（CD86），但是这些抗体16C10和7C10中的两个显着抑制了IL-2的产生。 阻断CD28和B7.1（CD80）之间的主要激活信号与这些抗体同时允许CTLA-4和B7.1和/或B7.2的未受损或一致的相互作用代表对阳性共刺激的组合拮抗作用， 对负信号的激动作用。 这些抗体可以用作特异性免疫抑制剂，例如用于治疗自身免疫性疾病和预防器官移植排斥。

    Method for preparing anti-MIF antibodies
    7.
    发明授权
    Method for preparing anti-MIF antibodies 有权
    制备抗MIF抗体的方法

    公开(公告)号：US07294753B2

    公开(公告)日：2007-11-13

    申请号：US11143737

    申请日：2005-06-03

    申请人： William S Kloetzer ,  Nabil Hanna

    发明人： William S Kloetzer ,  Nabil Hanna

    IPC分类号： C12P21/00

    CPC分类号： A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/0331 ,  A61K39/3955 ,  A61K2039/505 ,  C07K14/52 ,  C07K16/24 ,  C12N15/8509 ,  A61K31/00 ,  A61K2300/00

    摘要： The specification provides methods of preparing high-affinity antibodies to a macrophage migration inhibitory factor (MIF) in animals in which the MIF gene has been homozygously knocked-out (MIF−/−). Also provided are methods of preparing hybridomas which produce the anti-MIF antibodies, methods of administering the antibodies to treat inflammatory or cancerous conditions and/or diseases modulated by MIF, as well as compositions comprising said high-affinity anti-MIF antibodies.

    摘要翻译： 本说明书提供了在MIF基因已经被纯合敲除的动物中制备巨噬细胞迁移抑制因子（MIF）的高亲和力抗体的方法（MIF）。 还提供了制备产生抗MIF抗体的杂交瘤的方法，施用抗体以治疗炎性或癌性病症和/或由MIF调节的疾病的方法，以及包含所述高亲和力抗MIF抗体的组合物的方法。

    IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS
    8.
    发明申请
    IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS 失效
    识别某些抗体与人B7.1和B7.2共刺激抗原之间的独特结合相互作用

    公开(公告)号：US20070128185A1

    公开(公告)日：2007-06-07

    申请号：US11553302

    申请日：2006-10-26

    申请人： Darrell Anderson ,  Nabil Hanna ,  Peter Brams

    发明人： Darrell Anderson ,  Nabil Hanna ,  Peter Brams

    IPC分类号： A61K39/395 ,  C07K16/28

    CPC分类号： C07K16/00 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/70532 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92

    摘要： The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-I and b7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

    摘要翻译： 本发明涉及对人B7.1抗原（CD80）特异性并且能够抑制B7.1与CD28受体的结合并且不能抑制B7.1结合的抗体的鉴定 到CTLA-4受体。 尽管存在第二活化配体B7.2（CD86），但是这些抗体16C10和7C10中的两个显着抑制了IL-2的产生。 使用这些抗体阻断CD28和B7.1（CD80）之间的主要激活信号，同时允许CTLA-1和b7.1和/或B7.2的未受损或一致的相互作用代表对阳性共刺激的组合拮抗作用， 对负信号的激动作用。 这些抗体可以用作特异性免疫抑制剂，例如用于治疗自身免疫性疾病和预防器官移植排斥。

    Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
    9.
    发明授权
    Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 有权
    使用不抑制CD80与CTLA-4结合的抗CD80抗体治疗B细胞淋巴瘤

    公开(公告)号：US07153508B2

    公开(公告)日：2006-12-26

    申请号：US10073138

    申请日：2002-02-13

    申请人： Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    发明人： Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    IPC分类号： A61K39/395 ,  C07K16/28

    CPC分类号： C07K16/00 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/70532 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92

    摘要： The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signaling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

    摘要翻译： 本发明涉及对人B7.1抗原（CD80）特异性并且能够抑制B7.1与CD28受体的结合并且不能抑制B7.1结合的抗体的鉴定 到CTLA-4受体。 尽管存在第二活化配体B7.2（CD86），但是这些抗体16C10和7C10中的两个显着抑制了IL-2的产生。 阻断CD28和B7.1（CD80）之间的主要激活信号与这些抗体同时允许CTLA-4和B7.1和/或B7.2的未受损或一致的相互作用代表对阳性共刺激的组合拮抗作用， 对负信号的激动作用。 这些抗体可以用作特异性免疫抑制剂，例如用于治疗自身免疫性疾病和预防器官移植排斥。